| Dr Faoud Ishmael, MD | |
|
1850 E Park Ave Ste 201, State College, PA 16803 | |
| (844) 278-4600 | |
| (814) 235-1133 |
| Full Name | Dr Faoud Ishmael |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 20 Years |
| Location | 1850 E Park Ave Ste 201, State College, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275670028 | NPI | - | NPPES |
| 017861600 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | MD437187 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mount Nittany Medical Center | State college, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mount Nittany Medical Center Health Services Inc | 8426136797 | 196 |
News Archive
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia, according to a study led in part by Dana-Farber Cancer Institute investigators.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.
Cellular Dynamics International (CDI) and Hoffmann-La Roche Inc. (Roche) today announced a workshop to be held during the Society of Toxicology Annual Meeting in Salt Lake City, UT, on March 7 - 11.
The latest advancement in prostate cancer detection is magnetic resonance imaging and ultrasound fusion-guided biopsy, which offers benefits for both patient and physician.
Brain-imaging studies performed in animals at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory provide researchers with clues about why an increasingly popular recreational drug that causes hallucinations and motor-function impairment in humans is abused.
› Verified 8 days ago
| Entity Name | Mount Nittany Medical Center Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164691499 PECOS PAC ID: 8426136797 Enrollment ID: O20081021000240 |
News Archive
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia, according to a study led in part by Dana-Farber Cancer Institute investigators.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.
Cellular Dynamics International (CDI) and Hoffmann-La Roche Inc. (Roche) today announced a workshop to be held during the Society of Toxicology Annual Meeting in Salt Lake City, UT, on March 7 - 11.
The latest advancement in prostate cancer detection is magnetic resonance imaging and ultrasound fusion-guided biopsy, which offers benefits for both patient and physician.
Brain-imaging studies performed in animals at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory provide researchers with clues about why an increasingly popular recreational drug that causes hallucinations and motor-function impairment in humans is abused.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Faoud Ishmael, MD 1850 E Park Ave Ste 201, State College, PA 16803-6706 Ph: (844) 278-4600 | Dr Faoud Ishmael, MD 1850 E Park Ave Ste 201, State College, PA 16803 Ph: (844) 278-4600 |
News Archive
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia, according to a study led in part by Dana-Farber Cancer Institute investigators.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.
Cellular Dynamics International (CDI) and Hoffmann-La Roche Inc. (Roche) today announced a workshop to be held during the Society of Toxicology Annual Meeting in Salt Lake City, UT, on March 7 - 11.
The latest advancement in prostate cancer detection is magnetic resonance imaging and ultrasound fusion-guided biopsy, which offers benefits for both patient and physician.
Brain-imaging studies performed in animals at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory provide researchers with clues about why an increasingly popular recreational drug that causes hallucinations and motor-function impairment in humans is abused.
› Verified 8 days ago
Neil Baman, MD Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 200 Scenery Dr, State College, PA 16801 Phone: 814-231-4560 Fax: 814-231-6246 | |
Sebastian Sylvestre, MD Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 1850 E Park Ave Ste 201, State College, PA 16803 Phone: 814-234-8800 Fax: 814-235-1133 | |
Dr. Robert A. Mentyka, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 200 Scenery Dr, State College, PA 16801 Phone: 814-231-4560 Fax: 814-235-5512 |